Reply: To PMID 23564522

Affiliations

Comment

Yasuhiro Asahina et al. Hepatology. 2014 Aug.

. 2014 Aug;60(2):764.

doi: 10.1002/hep.27066. Epub 2014 Jun 18.

¹ Department of Gastroenterology and Hepatology, Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, Japan.

No abstract available

Comment on

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Asahina Y, et al. Hepatology. 2013 Oct;58(4):1253-62. doi: 10.1002/hep.26442. Epub 2013 Aug 19. Hepatology. 2013. PMID: 23564522
Postinterferon α-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results?
Toyoda H, Kumada T, Tada T. Toyoda H, et al. Hepatology. 2014 Aug;60(2):762-3. doi: 10.1002/hep.27064. Epub 2014 Jun 18. Hepatology. 2014. PMID: 24519154 No abstract available.
Could postinterferon treatment α-fetoprotein levels truly predict hepatocarcinogenesis?
Lo GH. Lo GH. Hepatology. 2014 Aug;60(2):763. doi: 10.1002/hep.27065. Epub 2014 Jun 26. Hepatology. 2014. PMID: 24700196 No abstract available.